Home
Storia in 2 fonti
Why Is Regeneron Stock Sinking Monday? - Regeneron Pharmaceuticals (NASDAQ:REGN)
Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free survival in the high-dose arm.
- ·
biopharmadive.com
Regeneron immunotherapy combo comes up short in melanoma trial
A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out…
- ·
benzinga.com
Why Is Regeneron Stock Sinking Monday? - Regeneron Pharmaceuticals (NASDAQ:REGN)
Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free survival in the high-dose arm.